Adverse childhood experiences (ACEs) are known to contribute to mental health issues and interfere with response to mental health interventions. Psychedelics have been found to improve mental health outcomes; however, the exploration of the effects of psychedelics on mental health in those with higher ACEs remains limited. The present study aimed to examine mental health outcomes and acute subjective effects of ceremonial psychedelic use across the spectrum of ACE severity.
Method:
Prospective observational survey data were collected from a convenience sample (N = 570) of individuals who participated in psychedelic ceremonies. ACE severity was measured at baseline using the validated ACE-Questionnaire. Acute psychedelic experiences (mystical, emotional breakthrough, and challenging experiences) were assessed 1-day postpsychedelic use. Validated measures of mental well-being, experiential avoidance, and trait anxiety were obtained before, and 2- and 4-weeks postpsychedelic experience.
Results:
A regression analysis found that ACEs significantly moderated the relationship between time and mental health outcomes. Relative to lower ACEs, higher ACEs were associated with greater improvements in mental health across time, corrected for baseline. Spearman’s correlation showed that ACEs were significantly positively correlated with emotional breakthrough (rs = 0.15) and mystical experiences (rs =.12). Among individuals with ACEs ≥4, mystical and emotional breakthrough experiences were positively associated with well-being 2 (adj. r2 = 0.576 and 0.526) and 4 weeks (adj. r2 = 0.438 and 0.463, respectively) postpsychedelic experience (controlling for baseline well-being). Mystical experiences were negatively associated with experiential avoidance (adj. r2 = 0.716), and emotional breakthrough experiences were negatively associated with anxiety, 4 weeks postpsychedelic experience (adj. r2 = 0.401), controlling for baseline. Acute experiences did not significantly moderate the association between ACEs and mental health outcomes.
Discussion:
ACEs were associated with improvements in mental health following psychedelic experiences. ACEs were positively correlated with emotional breakthrough and mystical experiences, which were associated with improved longer term mental health. Study limitations include the use of a convenience sample and noncontrolled design. This study’s findings tentatively inform the development of psychedelic therapy in those reporting ACEs.
AndaRF, BrownDW, DubeSR, et al.Adverse childhood experiences and chronic obstructive pulmonary disease in adults. Am J Prev Med, 2008; 34(5):396–403; doi: 10.1016/j.amepre.2008.02.002
3.
CampbellJA, WalkerRJ, EgedeLE. Associations between adverse childhood experiences, high-risk behaviors, and morbidity in adulthood. Am J Prev Med, 2016; 50(3):344–352; doi: 10.1016/j.amepre.2015.07.022
4.
LoxtonD, ForderPM, CavenaghD, et al.The impact of adverse childhood experiences on the health and health behaviors of young Australian women. Child Abuse Negl, 2021; 111:104771; doi: 10.1016/j.chiabu.2020.104771
5.
AshtonK, BellisM, HughesK. Adverse childhood experiences and their association with health-harming behaviours and mental wellbeing in the Welsh adult population: A national cross-sectional survey. The Lancet, 2016; 388(S21):S21; doi: 10.1016/S0140-6736(16)32257-7
6.
BomysoadRN, FrancisLA. Adverse childhood experiences and mental health conditions among adolescents. J Adolesc Health, 2020; 67(6):868–870; doi: 10.1016/j.jadohealth.2020.04.013
7.
BriggsES, PriceIR. The relationship between adverse childhood experience and obsessive-compulsive symptoms and beliefs: The role of anxiety, depression, and experiential avoidance. J Anxiety Disord, 2009; 23(8):1037–1046; doi: 10.1016/j.janxdis.2009.07.004
8.
DaníelsdóttirHB, AspelundT, ShenQ, et al.Adverse childhood experiences and adult mental health outcomes. JAMA Psychiatry, 2024; 81(6):586–594; doi: 10.1001/jamapsychiatry.2024.0039
9.
NanniV, UherR, DaneseA. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. Am J Psychiatry, 2012; 169(2):141–151; doi: 10.1176/appi.ajp.2011.11020335
10.
NemeroffCB. Paradise Lost: The neurobiological and clinical consequences of childhood abuse and neglect. Neuron, 2016; 89(5):892–909; doi: 10.1016/j.neuron.2016.01.019
11.
KaratekinC. Adverse childhood experiences (ACEs) and help-seeking for health-related interventions in young adults. J Psychol, 2019; 153(1):6–22; doi: 10.1080/00223980.2018.1476316
12.
JohnsonMW, HendricksPS, BarrettFS, et al.Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther, 2019; 197:83–102; doi: 10.1016/j.pharmthera.2018.11.010
13.
Carhart-HarrisRL, BolstridgeM, RuckerJ, et al.Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry, 2016; 3(7):619–627; doi: 10.1016/S2215-0366(16)30065-7
14.
Carhart-HarrisR, GiribaldiB, WattsR, et al.Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med, 2021; 384(15):1402–1411; doi: 10.1056/NEJMoa2032994
15.
GoodwinGM, AaronsonST, AlvarezO, et al.Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med, 2022; 387(18):1637–1648; doi: 10.1056/NEJMoa2206443
16.
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197; doi: 10.1177/0269881116675513
17.
PeckSK, ShaoS, GruenT, et al.Psilocybin therapy for females with anorexia nervosa: A phase 1, open-label feasibility study. Nat Med, 2023; 29(8):1947–1953; doi: 10.1038/s41591-023-02455-9
18.
SpriggsMJ, KettnerH, Carhart-HarrisRL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord, 2021; 26(4):1265–1270; doi: 10.1007/s40519-020-01000-8
19.
Von RotzR, SchindowskiEM, JungwirthJ, et al.Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine, 2023; 56:101809; doi: 10.1016/j.eclinm.2022.101809
20.
SloshowerJ, ZeifmanRJ, GussJ, et al.Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: Results from an exploratory placebo-controlled trial. Sci Rep, 2024; 14(1):8833; doi: 10.1038/s41598-024-58318-x
21.
Agin-LiebesG, ZeifmanR, LuomaJB, et al.Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. J Psychopharmacol, 2022; 36(3):295–308; doi: 10.1177/02698811221080165
22.
PetridisPD, GrinbandJ, Agin-LiebesG, et al.Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. Nat Mental Health, 2024; 2(11):1408–1414; doi: 10.1038/s44220-024-00331-0
23.
ZeifmanRJ, WagnerAC, MonsonCMet al.How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. J Affect Disord, 2023; 334:100–112; doi: 10.1016/j.jad.2023.04.105
24.
Fuller-ThomsonE, BairdSL, DhrodiaR, et al.The association between adverse childhood experiences (ACEs) and suicide attempts in a population-based study. Child Care Health Dev, 2016; 42(5):725–734; doi: 10.1111/cch.12351
25.
ParfaitB, SeaseTB, SandozEK. Psychological inflexibility as a mediator of the relationship between adverse childhood experiences and dissociation. J Contextual Behav Sci, 2022; 23(2):92–97; doi: 10.1016/j.jcbs.2021.12.005
26.
YadenDB, GriffithsRR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci, 2021; 4(2):568–572; doi: 10.1021/acsptsci.0c00194
27.
HaijenECHM, KaelenM, RosemanL, et al.Predicting responses to psychedelics: A prospective study. Front Pharmacol, 2018; 9:897; doi: 10.3389/fphar.2018.00897
28.
RosemanL, NuttDJ, Carhart-HarrisRL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol, 2017; 8:974; doi: 10.3389/fphar.2017.00974
29.
StaufferCS, AndersonBT, OrtigoKM, et al.Psilocybin-Assisted group therapy and attachment: Observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience. ACS Pharmacol Transl Sci, 2021; 4(2):526–532; doi: 10.1021/acsptsci.0c00169
30.
SloshowerJ, SkosnikPD, Safi-AghdamH, et al.Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. J Psychopharmacol, 2023; 37(7):698–706; doi: 10.1177/02698811231154852
31.
BarrettFS, BradstreetMP, LeoutsakosJ-MS, et al.The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol, 2016; 30(12):1279–1295; doi: 10.1177/0269881116678781
32.
CarbonaroTM, BradstreetMP, BarrettFS, et al.Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol, 2016; 30(12):1268–1278; doi: 10.1177/0269881116662634
33.
KettnerH, RosasFE, TimmermannC, et al.Psychedelic communitas: Intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness. Front Pharmacol, 2021; 12:623985; doi: 10.3389/fphar.2021.623985
34.
Agin-LiebesG, EkmanE, AndersonB, et al.Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: An interpretive phenomenological analysis. J Humanist Psychol, 2024; 64(4):564–591; doi: 10.1177/00221678211022949
35.
KiragaMK, KuypersKPC, UthaugMV, et al.Decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees. Front Psychiatry, 2022; 13:883869; doi: 10.3389/fpsyt.2022.883869
36.
ZeifmanRJ, WagnerAC, WattsR, et al.Post-Psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry, 2020; 11:782; doi: 10.3389/fpsyt.2020.00782
37.
BallJS, LinksPS. Borderline personality disorder and childhood trauma: Evidence for a causal relationship. Curr Psychiatry Rep, 2009; 11(1):63–68; doi: 10.1007/s11920-009-0010-4
38.
HealyCJ, FrazierA, KirschS, et al.Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories. Prog Neuropsychopharmacol Biol Psychiatry, 2025; 138(2):111361; doi: 10.1016/j.pnpbp.2025.111361
39.
ZeifmanRJ, WagnerAC. Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder. J Contextual Behav Sci, 2020; 15:1–11; doi: 10.1016/j.jcbs.2019.11.001
40.
MarrocuA, KettnerH, WeissB, et al.Psychiatric risks for worsened mental health after psychedelic use. J Psychopharmacol, 2024; 38(3):225–235; doi: 10.1177/02698811241232548
41.
CardKG, GrewalA, ClossonK, et al.Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use. J Psychoactive Drugs, 2024; 56(5):616–626; doi: 10.1080/02791072.2023.2268640
42.
HealyCJ, LeeKA, D’AndreaW. Using psychedelics with therapeutic intent is associated with lower shame and complex trauma symptoms in adults with histories of childhood maltreatment. Chronic Stress Thousand Oaks Calif, 2021; 5:1–12; doi: 10.1177/24705470211029881
43.
PengY, IshakZ. Self-compassion as a mediator of attachment anxiety, attachment avoidance, and complex PTSD in college students with adverse childhood experiences. Sci Rep, 2025; 15(1):786; doi: 10.1038/s41598-024-84947-3
44.
NayakSM, JacksonH, SepedaND, et al.Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective, longitudinal survey. Front Psychiatry, 2023; 14:1199642; doi: 10.3389/fpsyt.2023.1199642
45.
RosemanL, HaijenE, Idialu-IkatoK, et al.Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory. J Psychopharmacol, 2019; 33(9):1076–1087; doi: 10.1177/0269881119855974
46.
RudenstineS, EspinosaA, McGeeAB, et al.Adverse childhood events, adult distress, and the role of emotion regulation. Traumatology (Tallahass Fla), 2019; 25(2):124–132; doi: 10.1037/trm0000176
47.
ShefflerJL, PiazzaJR, QuinnJM, et al.Adverse childhood experiences and coping strategies: Identifying pathways to resiliency in adulthood. Anxiety Stress Coping, 2019; 32(5):594–609; doi: 10.1080/10615806.2019.1638699
48.
JohnsonMW, Garcia-RomeuA, CosimanoMP, et al.Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol, 2014; 28(11):983–992; doi: 10.1177/0269881114548296
49.
MuttoniS, ArdissinoM, JohnC. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord, 2019; 258:11–24; doi: 10.1016/j.jad.2019.07.076
50.
RuckerJJ, JelenLA, FlynnS, et al.Psychedelics in the treatment of unipolar mood disorders: A systematic review. J Psychopharmacol, 2016; 30(12):1220–1229; doi: 10.1177/0269881116679368
51.
PeillJM, TrinciKE, KettnerH, et al.Validation of the psychological insight scale: A new scale to assess psychological insight following a psychedelic experience. J Psychopharmacol, 2022; 36(1):31–45; doi: 10.1177/02698811211066709
52.
TimmermannC, KettnerH, LethebyC, et al.Psychedelics alter metaphysical beliefs. Sci Rep, 2021; 11(1):22166; doi: 10.1038/s41598-021-01209-2
53.
GordonAR, CarrithersBM, PagniBA, et al.The Effect of psychedelics on individuals with a personality disorder: Results from two prospective cohort studies. Res Sq, 2024; doi: 10.21203/rs.3.rs-4203641/v1
54.
FelittiVJ, AndaRF, NordenbergD, et al.Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med, 1998; 14(4):245–258; doi: 10.1016/s0749-3797(98)00017-8
55.
DongM, AndaRF, FelittiVJ, et al.The interrelatedness of multiple forms of childhood abuse, neglect, and household dysfunction. Child Abuse Negl, 2004; 28(7):771–784; doi: 10.1016/j.chiabu.2004.01.008
56.
RahmanA, PerriA, DeeganA, et al.On becoming trauma-informed: Role of the Adverse childhood experiences survey in tertiary childhood and adolescent mental health services and the association with standard measures of impairment and severity. TPJ, 2018; 22(1):17–54; doi: 10.7812/TPP/17-054
57.
MeinckF, CosmaAP, MiktonC, et al.Psychometric properties of the Adverse Childhood Experiences Abuse Short Form (ACE-ASF) among Romanian high school students. Child Abuse Negl, 2017; 72:326–337; doi: 10.1016/j.chiabu.2017.08.016
58.
PakdamanS, UngerJB, ForsterM, et al.Childhood Trauma and Prescription Drug Misuse in a College Population. Subst Use Misuse, 2021; 56(1):140–144; doi: 10.1080/10826084.2020.1846056
59.
Fioravanti-BastosACM, CheniauxE, Landeira-FernandezJ. Development and validation of a short-form version of the Brazilian state-trait anxiety inventory. Psicol Reflex Crit, 2011; 24(3):485–494; doi: 10.1590/S0102-79722011000300009
60.
GámezW, ChmielewskiM, KotovR, et al.The brief experiential avoidance questionnaire: Development and initial validation. Psychol Assess, 2014; 26(1):35–45; doi: 10.1037/a0034473
61.
TennantR, HillerL, FishwickR, et al.The warwick-edinburgh mental well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes, 2007; 5:63; doi: 10.1186/1477-7525-5-63
62.
BarrettFS, JohnsonMW, GriffithsRR. Validation of the revised mystical experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol, 2015; 29(11):1182–1190; doi: 10.1177/0269881115609019
BrownVA. An Introduction to Linear Mixed-Effects Modeling in R. Adv Methods Pract Psychol Sci, 2021; 4(1):2515245920960351; doi: 10.1177/2515245920960351
65.
KuznetsovaA, BrockhoffPB, ChristensenRHB. LmerTest package: Tests in linear mixed effects models. J Stat Soft, 2017; 82(13):1–26; doi: 10.18637/jss.v082.i13
66.
Marques-QuinteiroP, VargasR, EiflerN, et al.Employee adaptive performance and job satisfaction during organizational crisis: The role of self-leadership. Eur J Work Organ Psychol, 2019; 28(1):85–100; doi: 10.1080/1359432X.2018.1551882
67.
SonuS, PostS, FeinglassJ. Adverse childhood experiences and the onset of chronic disease in young adulthood. Prev Med, 2019; 123:163–170; doi: 10.1016/j.ypmed.2019.03.032
68.
GoldensonJ, KitollariI, LehmanF. The relationship between ACEs Trauma-Related Psychopathology and Resilience in Vulnerable Youth: Implications for Screening and Treatment. J Child Adolesc Trauma, 2021; 14(1):151–160; doi: 10.1007/s40653-020-00308-y
69.
HughesK, BellisMA, HardcastleKA, et al.The effect of multiple adverse childhood experiences on health: A systematic review and meta-analysis. Lancet Public Health, 2017; 2(8):e356–e366; doi: 10.1016/S2468-2667(17)30118-4
70.
WilliamsMT, DavisAK, XinY, et al.People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs (Abingdon Engl), 2021; 28(3):215–226; doi: 10.1080/09687637.2020.1854688
71.
RoseJR. Memory, trauma, and self: Remembering and recovering from sexual abuse in psychedelic-assisted therapy. Jps, 2024; 8(3):336–348; doi: 10.1556/2054.2024.00363
72.
CassidyK, HealyC, HenjeE, et al.Childhood trauma, challenging experiences, and posttraumatic growth in ayahuasca use. Drug Sci Policy Law, 2024; 10:20503245241238316; doi: 10.1177/20503245241238316
73.
GoodwinGM, GreenAR, JohnsonP. 5-HT2 receptor characteristics in frontal cortex and 5-HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br J Pharmacol, 1984; 83(1):235–242; doi: 10.1111/j.1476-5381.1984.tb10140.x
74.
MurnaneKS. Serotonin 2A Receptors are a Stress Response System: Implications for Post-Traumatic Stress Disorder. Behav Pharmacol, 2019; 30(2 and 3-Spec Issue):151–162; doi: 10.1097/FBP.0000000000000459
75.
KaliaV, KnauftK. Emotion regulation strategies modulate the effect of adverse childhood experiences on perceived chronic stress with implications for cognitive flexibility. PLoS One, 2020; 15(6):e0235412; doi: 10.1371/journal.pone.0235412
76.
WolffM, EvensR, MertensLJ, et al.Learning to let go: A cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry, 2020; 11:5; doi: 10.3389/fpsyt.2020.00005
77.
WolffM, MertensLJ, WalterM, et al.The acceptance/avoidance-promoting experiences questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility. J Psychopharmacol, 2022; 36(3):387–408; doi: 10.1177/02698811211073758
78.
GandyS. Predictors and potentiators of psychedelic-occasioned mystical experiences. Jps, 2022; 6(1):31–47; doi: 10.1556/2054.2022.00198
79.
RussSL, Carhart-HarrisRL, MaruyamaG, et al.States and traits related to the quality and consequences of psychedelic experiences. Psychol Conscious Theory Res Pract, 2019; 6(1):1–21; doi: 10.1037/cns0000169
80.
LoiNM, JamiesonGA. The role of absorption, fantasy proneness and hypnosis in response to trauma. Aust J Clin Exp Hypn, 2011; 38(2):132–154.
81.
VizeliP, StuderusE, HolzeF, et al.Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants. Transl Psychiatry, 2024; 14(1):357; doi: 10.1038/s41398-024-03074-9
82.
WojcikKD, CoxDW, KealyD. Adverse childhood experiences and shame- and guilt-proneness: Examining the mediating roles of interpersonal problems in a community sample. Child Abuse Negl, 2019; 98:104233; doi: 10.1016/j.chiabu.2019.104233
83.
HealyC, FrazierA, KirschS, et al.Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories. PsyArXiv Preprints, 2024; doi: 10.31234/osf.io/3rbxe
84.
MathaiDS, RobertsDE, NayakSM, et al.Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. PsyArXiv Preprints, 2024; doi: 10.31234/osf.io/hm6jn
85.
BenedanL, PowellMB, ZajacR, et al.Suggestibility in neglected children: The influence of intelligence, language, and social skills. Child Abuse Negl, 2018; 79:51–60; doi: 10.1016/j.chiabu.2018.01.005
86.
SzigetiB, WeissB, RosasFE, et al.Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychol Med, 2024; 54(8):1717–1724; doi: 10.1017/S0033291723003653
87.
CoetzeeRH, RegelS. Eye movement desensitisation and reprocessing: An update. Adv Psychiatr Treat, 2005; 11(5):347–354; doi: 10.1192/apt.11.5.347
88.
DavisAK, XinY, SepedaND, et al.Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress (Thousand Oaks), 2021; 5:24705470211035607; doi: 10.1177/24705470211035607
89.
HübnerS, HaijenE, KaelenM, et al.Turn on, tune in, and drop out: Predictors of attrition in a prospective observational cohort study on psychedelic Use. J Med Internet Res, 2021; 23(7):e25973; doi: 10.2196/25973
90.
WalshD, McCartneyG, SmithM, et al.Relationship between childhood socioeconomic position and adverse childhood experiences (ACEs): a systematic review. J Epidemiol Community Health, 2019; 73(12):1087–1093; doi: 10.1136/jech-2019-212738
91.
Lê-ScherbanF, WangA, CourtsKA, et al.A short adverse experiences measure among mothers of young childhoodren. Pediatrics, 2024; 153(4):e2023063882; doi: 10.1542/peds.2023-063882
92.
WadeR, BeckerBD, BevansKB, et al.Development and evaluation of a short adverse childhood experiences measure. Am J Prev Med, 2017; 52(2):163–172; doi: 10.1016/j.amepre.2016.09.033
93.
ChegeniM, HaghdoostA, ShahrbabakiM, et al.Validity and reliability of the Persian version of the adverse childhood experiences abuse short form. J Educ Health Promot, 2020; 9(1):140; doi: 10.4103/jehp.jehp_15_20
94.
AndaRF, PorterLE, BrownDW. Inside the adverse childhood experience score: Strengths, limitations, and misapplications. Am J Prev Med, 2020; 59(2):293–295; doi: 10.1016/j.amepre.2020.01.009
95.
BernsteinDP, AhluvaliaT, PoggeD, et al.Validity of the childhood trauma questionnaire in an adolescent psychiatric population. J Am Acad Child Adolesc Psychiatry, 1997; 36(3):340–348; doi: 10.1097/00004583-199703000-00012
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
